

HALOZYME THERAPEUTICS INC  
Form SC 13G/A  
February 13, 2006

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 1)\***

Halozyme Therapeutics, Inc.

---

(Name of Issuer)

Common Stock, par value \$0.001 per share

---

(Title of Class of Securities)

40637H109

---

(CUSIP Number)

December 31, 2005

---

(Date of Event Which Requires Filing of this Statement)

Edgar Filing: HALOZYME THERAPEUTICS INC - Form SC 13G/A

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 40637H109

1. Names of Reporting Persons.

I.R.S. Identification Nos. of above persons (entities only).

**QVT Financial LP**

11-3694008

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

3. SEC Use Only

4. Citizenship or Place of Organization

Delaware

5.  Sole Voting Power

Number of 0

Shares  6. Shared Voting Power

Beneficially

Owned by 6,036,779 shares of common stock

Each  7. Sole Dispositive Power

Reporting

Person 0

With:  8. Shared Dispositive Power

6,036,779 shares of common stock

9. Aggregate Amount Beneficially Owned by Each Reporting Person

6,036,779 shares of common stock

Edgar Filing: HALOZYME THERAPEUTICS INC - Form SC 13G/A

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)

9.999%

12. Type of Reporting Person (See Instructions)

PN

Page 2 of 9 pages

CUSIP No. 40637H109

1. Names of Reporting Persons.

I.R.S. Identification Nos. of above persons (entities only).

**QVT Financial GP LLC**

11-3694007

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

3. SEC Use Only

4. Citizenship or Place of Organization

Delaware

5.  Sole Voting Power

Number of 0

Shares  6. Shared Voting Power

Beneficially

Owned by 6,036,779 shares of common stock

Each  7. Sole Dispositive Power

Reporting

Person 0

With:  8. Shared Dispositive Power

**6,036,779 shares of common stock**

9. Aggregate Amount Beneficially Owned by Each Reporting Person

**6,036,779 shares of common stock**

Edgar Filing: HALOZYME THERAPEUTICS INC - Form SC 13G/A

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)

9.999%

12. Type of Reporting Person (See Instructions)

OO

Page 3 of 9 pages

CUSIP No. 40637H109

1. Names of Reporting Persons.

I.R.S. Identification Nos. of above persons (entities only).

**QVT Fund LP**

98-0415217

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

3. SEC Use Only

4. Citizenship or Place of Organization

Cayman Islands

5. Sole Voting Power

Number of 0

Shares 6. Shared Voting Power

Beneficially

Owned by 5,611,779 shares of common stock

Each 7. Sole Dispositive Power

Reporting

Person 0

With: 8. Shared Dispositive Power

5,611,779 shares of common stock

9. Aggregate Amount Beneficially Owned by Each Reporting Person

5,611,779 shares of common stock

Edgar Filing: HALOZYME THERAPEUTICS INC - Form SC 13G/A

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)

9.295%

12. Type of Reporting Person (See Instructions)

PN

Page 4 of 9 pages



CUSIP No. 40637H109

1. Names of Reporting Persons.

I.R.S. Identification Nos. of above persons (entities only).

**QVT Associates GP LLC**

01-0798253

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

3. SEC Use Only

4. Citizenship or Place of Organization

Delaware

5.  Sole Voting Power

Number of 0

Shares  6. Shared Voting Power

Beneficially

Owned by 5,611,779 shares of common stock

Each  7. Sole Dispositive Power

Reporting

Person 0

With:  8. Shared Dispositive Power

5,611,779 shares of common stock

9. Aggregate Amount Beneficially Owned by Each Reporting Person

5,611,779 shares of common stock

Edgar Filing: HALOZYME THERAPEUTICS INC - Form SC 13G/A

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)

9.295%

12. Type of Reporting Person (See Instructions)

OO

Page 5 of 9 pages

**Item 1 (a).** Name of Issuer

Halozyme Therapeutics, Inc. (the Issuer )

**Item 1 (b).** Address of Issuer's Principal Executive Offices

The address of the Issuer's principal executive offices is:

11588 Sorrento Valley Road, Suite 17, San Diego, CA 92121

**Item 2 (a).** Name of Person Filing

**Item 2 (b).** Address of Principal Business Office or, if none, Residence

**Item 2 (c).** Citizenship

QVT Financial LP

527 Madison Avenue, 8th Floor

New York, New York 10022

Delaware Limited Partnership

QVT Financial GP LLC

527 Madison Avenue, 8th Floor

New York, New York 10022

Delaware Limited Liability Company

QVT Fund LP

Walkers SPV, Walkers House

P.O. Box 908GT

Mary Street

George Town, Grand Cayman, Cayman Islands

Cayman Islands Limited Partnership

QVT Associates GP LLC

527 Madison Avenue, 8th Floor

New York, New York 10022

Delaware Limited Liability Company

**Item 2 (d).** Title of Class of Securities

The title of the securities is common stock, par value \$0.001 per share (the Common Stock ).

**Item 2 (e).** CUSIP Number

The CUSIP number of the Common Stock is 40637H109.

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

Edgar Filing: HALOZYME THERAPEUTICS INC - Form SC 13G/A

- (a) .. Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b) .. Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) .. Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) .. Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) .. An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) .. An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) .. A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) .. A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) .. A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) .. Group, in accordance with § 240.13d-1(b)(1)(ii)(J).

Page 6 of 9 pages

**Item 4. Ownership.**

(a) Amount beneficially owned:

QVT Financial LP ( QVT Financial ) is the investment manager for QVT Fund LP (the Fund ), which beneficially owns 5,611,779 shares of Common Stock, consisting of 5,285,000 shares of Common Stock and 326,779 warrants to purchase additional Common Shares (the Warrants ). QVT Financial is also the investment manager for a separate discretionary account managed for Deutsche Bank AG (the Separate Account ), which holds 425,000 shares of Common Stock. QVT Financial has the power to direct the vote and disposition of the Common Stock held by each of the Fund and the Separate Account. Accordingly, QVT Financial may be deemed to be the beneficial owner of an aggregate amount of 6,036,779 shares of Common Stock, consisting of the shares owned or eligible for purchase by the Fund and the shares held in the Separate Account.

The aggregate number of shares underlying the Warrants is 960,000. Because the Warrants contain an issuance limitation prohibiting the Fund from exercising the Warrants to the extent that such exercise would result in beneficial ownership by the Fund or QVT Financial of more than 9.999% of the Common Shares then issued and outstanding, the Warrants currently are exercisable for 326,779 shares of Common Stock. This limitation may not be waived.

The approximate percentage of shares of Common Stock reported beneficially owned by each reporting person herein is based upon 60,373,818 shares outstanding, which reflects the sum of (i) 60,047,039 shares of Common Stock issued and outstanding as of December 16, 2005, and (ii) the 326,779 shares of Common Stock underlying the Warrants.

QVT Financial GP LLC, as General Partner of QVT Financial, may be deemed to beneficially own the same number of shares of Common Stock reported by QVT Financial. QVT Associates GP LLC, as General Partner of the Fund, may be deemed to beneficially own the same number of shares of Common Stock reported by the Fund.

Each of QVT Financial and QVT Financial GP LLC disclaim beneficial ownership of the shares of Common Stock beneficially owned by the Fund and the shares of Common Stock held in the Separate Account. QVT Associates GP LLC disclaims beneficial ownership of all shares of Common Stock beneficially owned by the Fund, except to the extent of its pecuniary interest therein.

(b) Percent of class:

See Item 11 of the Cover Pages to this Schedule 13G.

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote

0

(ii) Shared power to vote or to direct the vote

See item (a) above.

(iii) Sole power to dispose or to direct the disposition of

0

(iv) Shared power to dispose or to direct the disposition of

See item (a) above.

**Item 5. Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. "

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

---

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 13, 2006

**QVT FINANCIAL LP**

By QVT Financial GP LLC,

its General Partner

By:  /s/ Lars Bader

Name: Lars Bader  
Title: Managing Member

By:  /s/ Tracy Fu

Name: Tracy Fu  
Title: Managing Member

**QVT FINANCIAL GP LLC**

By:  /s/ Lars Bader

Name: Lars Bader  
Title: Managing Member

By:  /s/ Tracy Fu

Name: Tracy Fu  
Title: Managing Member

**QVT FUND LP**

By QVT Associates GP LLC,

its General Partner

By:  /s/ Lars Bader

Name: Lars Bader  
Title: Managing Member

By:  /s/ Tracy Fu

Name: Tracy Fu  
Title: Managing Member

**QVT ASSOCIATES GP LLC**

By:  /s/ Lars Bader

Name: Lars Bader  
Title: Managing Member

By:  /s/ Tracy Fu

Name: Tracy Fu  
Title: Managing Member

EXHIBIT A

JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G signed by each of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Dated: February 13, 2006

**QVT FINANCIAL LP**

By QVT Financial GP LLC,

its General Partner

By: /s/ Lars Bader

Name: Lars Bader  
Title: Managing Member

By: /s/ Tracy Fu

Name: Tracy Fu  
Title: Managing Member

**QVT FINANCIAL GP LLC**

By: /s/ Lars Bader

Name: Lars Bader  
Title: Managing Member

By: /s/ Tracy Fu

Name: Tracy Fu  
Title: Managing Member

**QVT FUND LP**

By QVT Associates GP LLC,

its General Partner

By: /s/ Lars Bader

Name: Lars Bader  
Title: Managing Member

By: /s/ Tracy Fu

Name: Tracy Fu  
Title: Managing Member

**QVT ASSOCIATES GP LLC**

By: /s/ Lars Bader

Name: Lars Bader  
Title: Managing Member

By: /s/ Tracy Fu

Name: Tracy Fu  
Title: Managing Member